Insider Buying: PROCEPT BioRobotics (NASDAQ:PRCT) Director Purchases $4,278,152.68 in Stock

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Director Antal Rohit Desai acquired 167,246 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were acquired at an average price of $25.58 per share, with a total value of $4,278,152.68. Following the completion of the transaction, the director owned 167,246 shares in the company, valued at $4,278,152.68. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Antal Rohit Desai also recently made the following trade(s):

• On Monday, March 9th, Antal Rohit Desai bought 98,699 shares of PROCEPT BioRobotics stock. The stock was acquired at an average price of $24.55 per share, for a total transaction of $2,423,060.45.
• On Friday, March 6th, Antal Rohit Desai purchased 160,317 shares of PROCEPT BioRobotics stock. The stock was bought at an average price of $23.59 per share, for a total transaction of $3,781,878.03.

PROCEPT BioRobotics Price Performance

Shares of PROCEPT BioRobotics stock traded up $1.04 during midday trading on Monday, hitting $25.26. 2,163,428 shares of the company traded hands, compared to its average volume of 1,640,943. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -14.77 and a beta of 1.03. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.77 and a current ratio of 6.85. The firm’s fifty day moving average price is $29.11 and its 200-day moving average price is $32.83. PROCEPT BioRobotics Corporation has a 12 month low of $19.35 and a 12 month high of $66.85.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.The company had revenue of $76.38 million for the quarter, compared to the consensus estimate of $93.70 million. During the same period in the previous year, the firm posted ($0.35) EPS. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. As a group, sell-side analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed a series of large open‑market purchases March 5–9, increasing his stake to 426,262 shares; the three Form 4 filings show roughly $10.5M of insider buying over those days — a strong bullish signal that executives view the stock as undervalued. Insider Purchase Filings
• Positive Sentiment: Research coverage was initiated at Robert W. Baird, which can increase visibility and trading interest (Baird’s note content/rating not included in the filing). Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold small stakes (6,721 and 6,892 shares respectively on March 6) for a combined ~13.6k shares (~$322k), likely personal liquidity rather than a company signal given the scale relative to the director’s purchases. Kevin Waters Sale Filing Alaleh Nouri Sale Filing
• Negative Sentiment: Two law firms (Levi & Korsinsky and Schall) announced securities‑fraud investigations related to PROCEPT’s prior guidance and statements (citing prior revenue targets and handpiece pricing comments). Such investigations raise the risk of litigation, distraction and potential disclosures or restatements — a clear negative catalyst for sentiment. Levi & Korsinsky Investigation Notice Schall Law Firm Investigation Notice

Hedge Funds Weigh In On PROCEPT BioRobotics

Several institutional investors have recently made changes to their positions in PRCT. Caitong International Asset Management Co. Ltd raised its stake in PROCEPT BioRobotics by 570.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,146 shares of the company’s stock worth $36,000 after buying an additional 975 shares during the period. Virtu Financial LLC acquired a new stake in shares of PROCEPT BioRobotics in the 4th quarter worth about $469,000. T. Rowe Price Investment Management Inc. boosted its stake in PROCEPT BioRobotics by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after purchasing an additional 1,218,815 shares during the last quarter. Invesco Ltd. raised its stake in shares of PROCEPT BioRobotics by 19.8% in the fourth quarter. Invesco Ltd. now owns 43,570 shares of the company’s stock worth $1,371,000 after purchasing an additional 7,191 shares during the last quarter. Finally, EP Wealth Advisors LLC bought a new stake in PROCEPT BioRobotics during the fourth quarter worth $300,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

Analyst Ratings Changes

PRCT has been the subject of a number of recent research reports. Leerink Partners decreased their price objective on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Bank of America downgraded PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and cut their target price for the stock from $38.00 to $20.00 in a report on Thursday, February 26th. Piper Sandler reduced their price target on PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating on the stock in a research report on Thursday, February 26th. Oppenheimer reissued a “market perform” rating on shares of PROCEPT BioRobotics in a research note on Thursday, February 26th. Finally, Truist Financial decreased their target price on shares of PROCEPT BioRobotics from $47.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics has an average rating of “Hold” and a consensus target price of $40.82.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.